Treating obesity: does antagonism of NPY fit the bill?
In this issue of Cell Metabolism, Erondu et al., (2006) identify a selective neuropeptide Y5 receptor antagonist that, as predicted from rodent studies, results in weight loss when administered to overweight and obese human subjects. In a one-year randomized placebo-controlled clinical trial, the weight loss was modest; the results support the emerging concept that NPY acts via overlapping and redundant energy homeostasis pathways.
Farooqi
Sadaf
S
University Department of Clinical Biochemistry, Addenbrooke's Hospital, Cambridge CB2 2QQ, United Kingdom.
D000284:Administration, Oral; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001835:Body Weight; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008954:Models, Biological; D009765:Obesity / Q000188:drug therapy*; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship
D019440:Anti-Obesity Agents; D017476:Receptors, Neuropeptide Y; C100568:neuropeptide Y5 receptor